



# ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

12<sup>th</sup> February 2018

Mr. Anish Kumar  
Assistant Vice President - Listing  
Metropolitan Stock Exchange of India Ltd  
4th Floor, Vibgyor Towers, Plot No. C 62,  
G Block, Opp. Trident Hotel,  
Bandra Kurla Complex, Bandra (E),  
**MUMBAI – 400 098**

Dear Sir,

**Sub: Unaudited Financial Results for the quarter ended 31<sup>st</sup> December 2017**  
**Ref: Circular No.MSE/LIST/5903/2018 dated 1.1.2018**  
**Symbol: AFDIL, Series: BE**

We refer to our letter dated 1<sup>st</sup> February 2018 informing you of our Board Meeting that is scheduled today. The Meeting of the Board of Directors commenced at 2.00pm and concluded at 3.00pm. The Board approved unaudited financial results for the quarter ended 31<sup>st</sup> December 2017.

We are enclosing a copy of the Unaudited Financial Results for the quarter ended 31<sup>st</sup> December 2017, which were taken on record at the meeting of the Directors of the Company held today at Bangalore and the Limited Review Report, for your information.

Please take the above information on record.

Thanking you,

Yours faithfully,  
for Anglo-French Drugs & Industries Ltd.

  
**B. Subbarayalu**  
Compliance Officer

Encl: A/a

BS:kg

LIMITED REVIEW REPORT

Review Report to  
The Board of Directors of  
Anglo-French Drugs & Industries Limited,  
41, 3<sup>rd</sup> Cross, V Block, Rajajinagar,  
Bangalore-560010

We have reviewed the accompanying statement of standalone unaudited financial results of **Anglo-French Drugs & Industries Limited** ("the Company") for the quarter and nine months ended December 31, 2017 ("the Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with the aforesaid Indian Accounting Standards i.e. 'Ind AS' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



The unaudited financial results for the quarter and nine months ended December 31, 2016 included in the Statement, are based on the previously issued results of the Company prepared in accordance with the Accounting Standards as per Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP). Those unaudited financial results prepared under previous GAAP were reviewed by the predecessor auditor, whose limited review report dated January 30, 2017 expressed an unmodified conclusion on those unaudited financial results. Management has adjusted those unaudited financial results for the differences in the accounting principles adopted by the Company on transition to Indian Accounting Standards ("Ind AS") and presented a reconciliation for the same, which has been approved by the Company's Board of Directors but have not been subject to review.

Our report is not modified in respect of this matter.



Place: Kolkata

Date: 12-02-2018

For KAMG & ASSOCIATES  
Chartered Accountants  
Firm Registration No.311027E

A handwritten signature in black ink, appearing to read "Koushik Roy".

Koushik Roy  
(Partner)

Membership No. 050066

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS WHICH ENDED ON 31ST DECEMBER 2017

(Rs in Lacs, except No of equity shares & Earning per share)

PARTICULARS	3 months ended (31/12/2017) (Un-Audited)	3 months ended (30/09/2017) (Un-Audited)	3 months ended (31/12/2016) (Un-Audited)	9 months ended (31/12/2017) (Un-Audited)	9 months ended (31/12/2016) (Un-Audited)
<b>1. Income</b>					
(a) Revenue from operations	3211	2934	3434	8026	9670
(b) Other Income	6	25	6	38	33
<b>Total Income</b>	<b>3217</b>	<b>2959</b>	<b>3440</b>	<b>8064</b>	<b>9703</b>
<b>2. Expenses</b>					
(a) Cost of Material Consumed	1606	741	753	3022	2904
(b) Purchase of Stock in Trade	616	654	1158	1662	2243
(c) Changes in Inventories of Finished goods, work in progress & Stock in Trade	(184)	249	(338)	146	(394)
(d) Employee Benefits Expenses	630	564	595	1784	1735
(e) Finance costs	109	104	81	301	239
(f) Depreciation and Amortisation Expense	38	48	42	134	127
(g) Other Expenses	695	675	1074	2236	2981
<b>Total Expenses</b>	<b>3510</b>	<b>3035</b>	<b>3365</b>	<b>9285</b>	<b>9835</b>
<b>3. Profit(+)/Loss(-) before Tax (1-2)</b>	<b>(293)</b>	<b>(76)</b>	<b>75</b>	<b>(1221)</b>	<b>(132)</b>
<b>4. Tax Expenses</b>					
i) Current Tax	0	0	0	0	0
ii) Deferred tax	(1)	0	0	(1)	0
<b>5. Profit(+)/Loss(-) for the period (3-4)</b>	<b>(292)</b>	<b>(76)</b>	<b>75</b>	<b>(1220)</b>	<b>(132)</b>
<b>6. Other Comprehensive Income</b>					
(i) Items that will not be reclassified to profit & Loss	(1)	(7)	0	(14)	(4)
(ii) Income tax on items that will not be reclassified to profit or loss	(1)	0	0	(1)	0
<b>Total Other Comprehensive Income</b>	<b>(2)</b>	<b>(7)</b>	<b>0</b>	<b>(15)</b>	<b>(4)</b>
<b>7. Total Comprehensive Income (5+6)</b>	<b>(294)</b>	<b>(83)</b>	<b>75</b>	<b>(1235)</b>	<b>(136)</b>
<b>8. Paid up equity share capital (Face value of Rs. 10 each)</b>	<b>11625000</b>	<b>11625000</b>	<b>11625000</b>	<b>11625000</b>	<b>11625000</b>
<b>9. Earnings/(Loss) Per Share (Face value of Rs. 10 each)</b>					
a) Basic	(25.12)	(6.54)	6.45	(104.95)	(11.35)
b) Diluted	(25.12)	(6.54)	6.45	(104.95)	(11.35)

Notes:

1 The company has adopted Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (Ind AS) from April 1, 2017, the date of transition being April 1, 2016. All the periods presented in the financial results & other financial information has been prepared in accordance with recognition & measurement principles laid down in Ind AS & discloses information required to be disclosed under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, read with SEBI circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016.

2 Reconciliation of the Net Profit/(Loss) as previously reported on account of transition from previous GAAP to Ind AS for the quarter and half year ended on December 31, 2016 is given below:

Particulars	(Rs. in lacs)	
	3 months ended 31.12.2016	9 months ended 31.12.2016
Net Profit/(Loss) as per previous GAAP (Indian GAAP)	73.00	(139.00)
Actuarial loss on employee defined benefit plan recognised in Other Comprehensive Income as per Ind AS 19	2.00	7.00
Net Profit/(Loss) as per Ind AS	75.00	(132.00)
Other Comprehensive Income	0.00	(4.00)
<b>Total Comprehensive income for the period</b>	<b>75.00</b>	<b>(136.00)</b>

3 The Ind AS financial results for the quarter and nine months which ended on 31.12.2016 have been compiled by the management after considering the necessary changes to give a true & fair value of the results in accordance with Ind AS. The Ind AS adjustments made in the financial results for the quarter and nine months which ended on 31.12.2016 has not been subjected to any limited review or audit.

4 Disclosure of figures for previous year ended 31st March 2017 and quarter ended 31st March 2017 is not mandatory as per Circular issued by SEBI no - CIR/CFD/FAC/62/2016 Dated 5th July 2016.

5 Unaudited financial results were reviewed by the Audit Committee and thereafter approved at the meeting of the Board of Directors held on February 12, 2018. The Statutory Auditors have carried out a limited review of the above financial data.

6 The Company has no reportable segments other than Pharmaceuticals division as per Ind AS.

7 The figures in respect of previous period have been regrouped/recast wherever necessary.

ANGLO-FRENCH DRUGS & INDUSTRIES LTD

*Abhay Kanoria*  
 ABHAY KANORIA  
 CHAIRMAN & MANAGING DIRECTOR

Place: Bengaluru  
 Date: 12-02-2018

